Imeik Technology Development Co., Ltd. (Stock Code: 300896) released its financial report for the period ending September 30, 2025. The report shows that Imeik's revenue for the first nine months of 2025 was 1.865 billion yuan, a year-on-year decrease of 21.49%. Net profit stood at 1.093 billion yuan, down 31%, while adjusted net profit was 976 million yuan, declining 36.2%.
In the third quarter of 2025, Imeik reported revenue of 566 million yuan, representing a 21.27% year-on-year increase. However, net profit fell 34.61% to 300 million yuan, and adjusted net profit dropped 42.37% to 255 million yuan.
The company received government subsidies totaling 48.93 million yuan in the first nine months, with 26.14 million yuan recorded in Q3 alone.
Jian Jun remains the largest shareholder, holding 31.09% as of September 30, 2025. Other major shareholders include Xiamen Zhixingjun Investment Management Partnership (6.42%), Shi Yifeng and Xiamen Danrui Investment Partnership (4.85% each), and Xiamen Kezhishang Investment Partnership (4.28%).
Shareholding structure remained relatively stable compared to June 30, 2025, though Hong Kong Securities Clearing Company and China Bank's Huabao CSI Healthcare ETF saw slight reductions in their stakes.
Imeik's stock closed at 163.54 yuan today, with a market capitalization of 49.486 billion yuan.
Comments